Indian Expert Dr. A. Ramkishan Appointed by WHO to Advisory Panel

HYDERABAD: Dr A. Ramkishan, deputy drugs controller of India, Central Drugs Standard Control Organization (CDSCO), has been appointed as one of the experts on the advisory panel on biological standardisation for four years by The World Health Organisation (WHO).

Dr Ramkishan who hails from Hyderabad is the first Indian doctor on the committee. He has 25 years of regulatory service in CDSCO which he joined in 1998 as a drug inspector in Mumbai.

A pharmacy graduate from Kakatiya University, Dr Ramkishan has been awarded 35 awards and honours.

Speaking to Deccan Chronicle Dr Ramkishan said, “The opportunity came on the basis of scientific capacity and expertise and experience in the field of pharmaceutical sciences as well as publications and regulatory experience. For the first time a regulator has been chosen on the panel and this is a huge opportunity for me.”

Related Posts

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Shares of Mankind Pharma fell more than 2% on 16 October after the company announced that it has signed an agreement to acquire a 70% stake in Belgium-based biotechnology company…

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs